. Because of the similar properties, often common chemotherapy protocols are used for the different manifestations of APUD tumours (Kelsen et al., 1982; Kessinger et al., 1983) . The most effective regimen for carcinoid tumours appears to be the combination of 5-fluorouracil and streptozotocin (Moertel, 1987) We conducted a trial with recombinant human IFN a-2b administered daily to patients with progressive malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. In addition, apart from the urinary 5-hydoxyindoleacetic acid (5-HIAA) level, the significance of platelet serotonin levels, serum or plasma levels of neuronspecific enolase (NSE), and urinary levels of serotonin, catecholamine and histamine as markers for the diagnosis and course of carcinoid tumours was studied during IFN a-2b treatment.
Summary Malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid are tumours with similar clinical features. In patients with unresectable or metastatic tumours leukocyte interferon (IFN) and recombinant human (rh) IFN have demonstrated efficacy. Twenty-four evaluable patients with progressive tumours were treated with 2.5 megaunits rh IFN a-2b, administered once daily subcutaneously, for a median duration of 7 months (range 0.5-37+). Two carcinoid patients demonstrated a response in tumour size, 80% showed stable disease (SD) . Sixty percent of the carcinoid patients with elevated urinary 5-hydroxyindoleacetic (5-HIAA) levels reached a biochemical partial response of the urinary 5-HIAA levels (median duration 13.5 months). In the patients with an islet cell or medullary tumour and an elevated tumour marker, the marker did not further increase. Of the 12 carcinoid patients evaluable for a symptomatic response, ten (83%) experienced a relieve of symptoms. IFN a-2b dose reduction or discontinuation due to toxicity was necessary in three and ten patients, respectively. No neutralising IFN a-2b antibodies developed despite prolonged treatment.
In conclusion, IFN a-2b had a beneficial effect in patients with progressive tumours, while long-term IFN a-2b treatment did not augment neutralising antibodies. In view of the IFN a-2b-related toxicity, administration of IFN a-2b on alternating days may be preferable.
Malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid are neuroendocrine tumours considered to originate from the neural crest (Pearse, 1969) . Together with others such as pheochromocytomas, neuroblastomas and small cell lung carcinomas, they share the ability to decarboxylate amines and are called APUD (amine precursor uptake and decarboxylation) tumours. Carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid in many cases have similar clinical features, often characterized by symptoms caused by their secretory products. The treatment should therefore address both tumour growth and these symptoms. As these tumours are often slowly progressive, surgery is the primary form of treatment. In patients with unresectable or metastatic tumours, a variety of cytotoxic drugs has been investigated (Kelsen et al., 1982; Kvols, 1986a; Moertel et al., 1980) . Because of the similar properties, often common chemotherapy protocols are used for the different manifestations of APUD tumours (Kelsen et al., 1982; Kessinger et al., 1983) . The most effective regimen for carcinoid tumours appears to be the combination of 5-fluorouracil and streptozotocin (Moertel, 1987) , with response rates of 33%. Recently, the combination streptozotocin and doxorubicin demonstrated considerable efficacy for islet cell tumours with a response rate of 69% (Moertel et al., 1992) . Studies in patients with carcinoid tumours or malignant endocrine pancreatic tumours treated with human leukocyte interferon (Oberg et al., 1983; Eriksson et al., 1986; Oberg et al., 1986; Eriksson et al., 1987; Oberg et al., 1989a) and recombinant human interferon alpha (IFN-a) (Oberg et al., 1989b; Moertel et al., 1989; Smith et al., 1987; Hanssen et al., 1989; Veenhof et al., 1992) We conducted a trial with recombinant human IFN a-2b administered daily to patients with progressive malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid. In addition, apart from the urinary 5-hydoxyindoleacetic acid (5-HIAA) level, the significance of platelet serotonin levels, serum or plasma levels of neuronspecific enolase (NSE), and urinary levels of serotonin, catecholamine and histamine as markers for the diagnosis and course of carcinoid tumours was studied during IFN a-2b treatment.
Finally, the development of neutralising IFN a-2b antibodies during long-term IFN treatment was studied, since neutralising antibodies can develop during IFN a-2b treatment (Spiegel et al., 1986; Oberg et al., 1989b (PR) , defined as over 50% reduction in the product of the greatest tumour diameter and its perpendicular for all measurable tumour lesions or a 50% reduction in the level of markers during two consecutive measurements not less than 4 weeks apart, was calculated from commencement of treatment until progression. Stable disease (SD) was defined as a reduction in measurable disease of less than 50%, or an increase in tumour size of less than 25% for at least 12 weeks. The biochemical response was defined as SD in case of less than 25% increase or less than 50% decrease of the marker levels during at least 4 weeks. The duration of SD was calculated from the start of treatment until progression. Progressive disease (PD) was the appearance of any new tumour lesions, the increase by more than 25% of measurable lesions or an increase in marker levels by more than 25% for a minimum of 4 weeks. At entry and at regular intervals during IFN treatment a complete physical examination, blood counts, and blood chemistry were performed.
Tumour markers
The concentration of 5-HIAA in 24 h urine (normal value 0.8-3.8 mmol mol'-creatinine), collected in 2 liter brown polypropylene bottles (Sarsted, Nuembrecht, Germany) containing 250 mg each of Na2S205 and EDTA as preservatives, was determined in ether extracts, using high performance liquid chromatography with fluorometric detection (Rosano et al., 1982) . Urinary catecholamines and metabolites levels were measured as described previously (Muskiet et al., 1979; Muskiet et al., 1981) , as were urinary histamine and metabolites levels in 24-h urine (Keyzer et al., 1983) .
Serotonin contents of urine (normal value 25-66 tsmol mol' creatinine) and of platelet rich plasma (normal value <0.5-33.3 nmol 1-' plasma) were determined using high performance liquid chromatography with fluorometric detection (Kema et al., 1992, in press). Platelet serotonin contents (normal value 2.8-5.4 nmol I0-9 platelets) were determined as described previously (Kwarts et al., 1984) . Venous blood samples were drawn in 10 ml vacutainer tubes (BectonDickinson, Meylan Cedex, France) containing 0.12 ml (0.34 mol I') EDTA solution, and were immediately put on ice. Platelet serotonin contents were calculated by dividing the concentration of serotonin in platelet rich plasma by its platelet concentration. Platelet concentrations were measured with a Coulter counter model S plus 4 (Coulter Electronics, Hialeah, USA).
Calcitonin serum levels (normal value < 300ngl1') were measured with a radioimmunoassay (Incstar Corporation, Stillwater, USA), as were gastrin serum levels (normal value < 100 ng -l1), Becton Dickinson and Company, New York, USA). NSE levels in haemoglobin free serum or plasma samples (normal value < 12.5 jig 1-l) were measured in duplicate with a radioimmunoassay (Pharmacia Diagnostics AB, Uppsala, Sweden), Tumor Necrosis Factor alpha (TNF-a) plasma levels (detection limit 5 ng l-') with a radioimmunoassay (Medgenix, Brussels, Belgium).
Anti IFN x-2b antibody serum levels were measured at entry and at any time point during IFN treatment at which there was a change in the clinal condition, tumour markers or tumour response. An enzyme-linked immunosorbent assay was used with as antibody the Intron A-specific mouse monoclonal antibody MC-16 (developed by TNO, Rijswijk, the Netherlands). As a negative control, pooled normal human serum obtained from healthy donors was included in the test. None of the donors had ever received IFN. This control serum contained naturally occurring anti-human IFN-a autoantibodies, the occurence of which has been reported previously (Ross et al., 1990 IFN a-2b effect on tumour lesions All patients had evaluable tumour lesions at entry. Twentytwo of the 24 patients were evaluable for response (Table  III) . After 2 weeks one patient was taken off study because cerebral metastases became manifest and in one patient treatment was discontinued within three months due to IFN a-2b-related fatigue and anorexia. One patient (mid-gut carcinoid) reached a CR of multiple liver metastases and one patient (mid-gut carcinoid) a PR of the solitary liver metastasis which permitted a hemihepatectomy. This last patient is without evidence of disease 31 + months after hemihepatectomy. Sixteen patients showed SD (median duration 6.5 months, range 3-37 + months). Two patients had PD at the first evaluation after three months of IFN a-2b treatment, while in two other patients (one patient with a carcinoid tumour and one patient with an islet cell tumour) treatment was discontinued within the first three months because of rapidly progressive disease.
IFN a-2b effect on tumour markers In six out of ten evaluable patients with a malignant carcinoid tumour and elevated pretreatment urine 5-HIAA levels a biochemical PR (median duration 13.5 months, range 1-37 + months) was achieved (Table IV) . In all patients responses occurred within the first three months of treatment. Four patients showed SD (median duration 6.5 months, range 3.5-17 months). In 60% of the carcinoid patients urine serotonin levels were elevated at entry. One patient had an increased urine serotonin level while having a normal urine 5-HIAA level. Of five patients evaluable for response, two had a biochemical PR (6 and 9 months, respectively) and three had SD (median duration 8 months, range 4.5 + -18 months). Eight carcinoid patients with increased pretreatment platelet serotonin contents were evaluable for response. Two patients, both with normal urine 5-HIAA levels, reached a biochemical PR (duration 5 and 6 months, respectively), while six patients, all with elevated urine 5-HIAA levels, had SD (median duration 12 months, range 6.5-27 months). Both patients with a medullary carcinoma of the thyroid gland and increased calcitonin serum levels at entry had also SD (duration 3.5 and 4 months respectively). The (Smith et al., 1987) . Although no tumour regressions were seen, 36% of the patients reached a 50% decrease in urinary 5-HIAA levels for a median time of 16 weeks (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] weeks). Other investigators observed in 40% of the patients a 50% reduction of the urinary 5-HIAA levels after one year of IFN a-2b treatment at a median dose of 5 MU/day sc (Hanssen et al., 1989) . In addition, a 50% reduction of the area of the largest hepatic metastasis was reached in one patient. A 50% reduction of urinary 5-HIAA levels was reached in 33% of patients with a metastatic carcinoid tumour treated with IFN a-2b at a dose of 3 MU thrice weekly sc (Veenhof et al., 1992 patients for a median time of 8 weeks (Moertel et al., 1989) with IFN a-2a intramuscularly three times weekly at doses of 6-24 mu m-2. Thirty-nine percent experienced a 50% reduction in elevated urinary 5-HIAA levels, with a median duration of 28 days. In 20% of the patients a PR of the indicator lesion was observed, with a median duration of 7 weeks (range . The results of our study and others with IFN a are similar to those in which human leukocyte IFN was administered to patients with a malignant carcinoid tumour and are far superior to results of current chemotherapeutic regimens (Kvols, 1986a; Moertel, 1987 (Anderson & Blood, 1987) . Grohn et al. treated two patients with medullary thyroid cancer with low dose IFN a-2b (Grohn et al., 1990) . This resulted in both patients in a decrease in calcitonin values (>50% and 25%, respectively) and improvement of diarrhoea. In the present study two patients with a medullary thyroid carcinoma and one patient with an islet cell carcinoma reached a s.d. of both the tumour and the biochemical marker.
Although urine 5-HIAA excretion is considered to be the most reliable biochemical parameter for a serotonin secreting tumour (Moertel, 1987) , determination of urinary and platelet serotonin levels may provide additional information (Feldman, 1986; Kema et al., 1992, in press ). In our study three carcinoid patients demonstrated elevated platelet serotonin levels (two patients) or increased urinary serotonin levels (one patient) in the absence of increased urine 5-HIAA excretion. In 50% of the patients with a malignant carcinoid tumour pretreatment levels of platelet serotonin were elevated. Other studies demonstrated similar percentages (Feldman, 1986; Kema et al., 1992, in press A role of NSE as a serum marker for the diagnosis of neuroendocrine neoplasms and for monitoring the response to therapy has been previously suggested (Prinz & Marangos, 1982; . NSE serum levels were reported to be increased in 40-50% of patients with APUD tumours. Our results confirm the role of serum NSE as a useful marker for APUD tumours as three patients did not have any other elevated tumour markers. In our study 31% of the patients had increased NSE levels. However, the group of patients (25%) evaluable for NSE response to IFN a-2b, was too small to allow conclusions with regard to a role in monitoring tumour response. Although early studies reported increased urine catecholamine and histamine levels in patients with carcinoid tumours (Feldman et al., 1974; Roberts II et al., 1979; Pernow & Waldenstrom, 1957) , we did not find elevated levels of these markers prior to IFN treatment. This may imply that these markers may be of limited value for the diagnosis of carcinoid tumours.
In our study 83% of the patients with symptoms of the carcinoid syndrome experienced a reduction in episodes of diarrhoea and/or flushing. Other studies using IFN-x (Smith et al., 1987; Hanssen et al., 1989; Moertel et al., 1989; Veenhof et al., 1992) report similar results. It is unlikely that increasing the IFN a-2b dose would have resulted in a higher symptomatic response rate (Moertel et al., 1989; Veenhof et al., 1992) .
Side effects of IFN a-2b were similar as described previously for studies in APUD tumours at comparable doses (Oberg et al., 1989b; Smith et al., 1987) . Some side effects (fatigue and anorexia) were observed more frequently by Moertel et al. which may be attributed to the considerably higher IFN adose used in that study (Moertel et al., 1989) . In our study, IFN dose-reduction or discontinuation was necessary in 56% of the patients. This percentage is high compared to other studies using comparable or moderately higher doses of IFN (Smith et al., 1987; Hanssen et al., 1989) . However, these data are difficult to compare, as different schedules for IFN dose-reduction may have been used.
One of the reasons of the relatively high frequency of IFN dose-reduction may have been the daily administration of IFN. In two studies using IFN three times per week the authors were able to administer higher cumulative IFN doses weekly (Smith et al., 1987; Oberg et al., 1989b antibodies in 15% of the carcinoid patients during the 6 months treatment period (Oberg et al., 1989b) . In cancer patients treated with systemic IFN a-2b, antibodies developed in 2.4% of the patients (Spiegel et al., 1986) . Thus, our data support the observation that anti IFN x-2b antibodies develop in only a small percentage of the patients treated with IFN a-2b. Therefore, treatment failure can only be attributed to anti IFN a-2b antibodies in a minority of the patients.
In conclusion, this study demonstrates that IFN a-2b can be of therapeutical use in patients with progressive malignant APUD tumours, as it may reduce both clinical symptoms and levels of biochemical tumour markers. As is the case for other treatment modalities the tumour-reducing effect is limited, with objective tumour responses occurring in only a small percentage of the patients. Although, in our opinion, the improvement in quality-of-life status of the patients outweighed the IFN a-2b-related side effects, a similar symptomatic improvement can be reached with somatostatin analogues almost without side effects (Kvols et al., 1986b; Vinik et al., 1989 ). However, not all patients resistant to IFN a treatment will benefit from somatostatin treatment and vice versa. To limit side effects, IFN a-2b administration on alternating days may be preferable. A role of NSE levels and platelet serotonin contents as additional markers for carcinoid tumours was confirmed. However, the group of patients evaluable for these markers was too small, to confirm a possible role of these markers in monitoring tumour response. Finally, it was demonstrated that even over a prolonged period of time the development of neutralising IFN x-2b antibodies did not occur, implying that IFN a-2b treatment can be maintained over a long period of time in patients with malignant APUD tumours without loss of efficacy. This is of clinical importance as our study also demonstrated that a number of patients benefitted from sustained IFN a-2b treatment over a number of years.
